Investment
Features
FeesSafety
Academy
More
Pluang+

New AI-focused ETF AIMG launches with 10 stocks but lacks performance data and transparency.

Market News
18 Sep 2026
24/7 Wall Street
View Source
Neutral
New AI-focused ETF AIMG launches with 10 stocks but lacks performance data and transparency.

The Defiance AI Magnificent 10 ETF (AIMG) recently launched, offering a concentrated portfolio of about ten AI-related stocks. However, with only six trading days, no published holdings, and no NAV history, investors have little data to assess its true AI exposure or performance. The fund charges a 0.61% fee, higher than broad tech ETFs, reflecting its active curation. Investors should treat AIMG as a small satellite holding and wait for more data before committing significant capital.

The Defiance AI Magnificent 10 ETF (AIMG) is a new AI-focused fund with limited trading history. For readers following Technology-sector US stocks, here is Pluang's market snapshot as of Sep 18, 2026 18:51 WIB: out of 150 stocks, 71 rose and 71 fell. Notable movers include BTDR at USD 11.43 with a 1.69% gain and a typical hold time of 15 days, NOK at USD 10.78 with a 1.60% gain and 62% buy order activity, and ACN at USD 187.35 down 1.55% with a typical hold time of 131 days.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
54 minutes ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App